Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 5/20 | 0.47 |
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.45 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 6/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786922 | 0.91 | CMA1 (0.69) | CMA1CA9CA12CA1CA2 | |
| SCHEMBL3780426 | 0.90 | CMA1 (0.67) | CMA1CA9CA12CA1CA2 | |
| SCHEMBL3785095 | 0.88 | CMA1 (0.67) | CMA1CA9CA12CA1CA2 | |
| SCHEMBL3782269 | 0.85 | CMA1 (0.69) | CMA1CA9CA12CA1CA2 | |
| SCHEMBL7464437 | 0.84 | CMA1 (0.79) | CMA1CA9CA12CA1CA2 | |
| SCHEMBL3788201 | 0.83 | CMA1 (0.85) | CMA1CA9CA12CA1CA2 | |
| SCHEMBL7469742 | 0.83 | CMA1 (0.69) | CMA1CA9CA12CA1CA2 | |
| SCHEMBL7463672 | 0.82 | CMA1 (1.00) | CMA1CA9CA12CA1CA2 | |
| SCHEMBL4450819 | 0.82 | CMA1 (0.67) | CMA1CA9CA12CA1CA2 | |
| SCHEMBL3785099 | 0.81 | CMA1 (0.66) | CMA1CA9CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | ASUBIO PHARMA CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7618977-B2 | Method of treating dermatitis comprising administering a chymase inhibitor | ASUBIO PHARMA CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1142586-B1 | USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-1174151-B1 | THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-1114035-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-6921766-B1 | Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-26 | — | — | US | disclosed |
| US-6867214-B1 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| US-6677344-B2 | Chymase inhibitor for the treatment of eosinophilia | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-6500835-B2 | FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION | SUNTORY LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20020187989-A1 | Preventive or therapeutic drugs for various eosinophilia-related diseases containg chymase inhibitors as the active ingredient | ASUBIO PHARMA CO., LTD. (JP) | 2002-12-12 | — | — | US | disclosed |
| US-20020183339-A1 | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020183338-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | ASUBIO PHARMA CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| EP-1192950-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR DERMATITISES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192949-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1174151-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR VARIOUS EOSINOPHILIA-RELATED DISEASES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1142586-A1 | INHIBITORS AGAINST VASCULAR LIPID DEPOSITION CONTAINING CHYMASE-INHIBITING SUBSTANCES | SUNTORY LIMITED (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187989-A1 | Preventive or therapeutic drugs for various eosinophilia-related diseases containg chymase inhibitors as the active ingredient | CMA1, SERPINB1, EPX | CA12 2265/4885CA1 2566/4885CA2 332/4885 |
| US-20020183339-A1 | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient | CMA1, SERPINB1, TSLP | CA12 1252/4885CA1 904/4885CA2 159/4885 |
| US-20020183338-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | CMA1, MMP1, SERPINB1 | CA12 1687/4885CA1 2655/4885CA2 426/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | CA12 4477/4885CA1 4668/4885CA2 2280/4885 |
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | CMA1, DNPEP, SERPINB1 | CA12 1154/4885CA1 632/4885CA2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.